Novo Nordisk Shares Plunge on Insulin's FDA Failure
Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
QuickTake: The Future of Fannie Mae and Freddie Mac
12:35 - In today’s “QuickTake,” Bloomberg's Vonnie Quinn takes a look at the road ahead for Fannie Mae and Freddie Mac under the Trump administration. She speaks on "Bloomberg Markets." (Source: Bloomberg)